Pressure BioSciences Nearing Complete Sellout on Pre-launch Offering of Game-Changing UST System for Processing CBD Oil Into Water-soluble Nanoemulsions

SOUTH EASTON, Massachusetts, March 12, 2020/ PRNewswire/– Pressure BioSciences, Inc. (OTCQB: PBIO) (” PBI” or the “Business”), a leader in the advancement and sale of broadly making it possible for, pressure-based instruments, consumables, and platform innovation services to the worldwide life sciences and other industries, today revealed that the Company has received an order from a new consumer, Can B Corp (OTC: CANBD), for one of its exclusive BaroShear K45 Ultra Shear Innovation ™ (” UST ™”)- based systems for processing CBD Oil into steady, successfully water-soluble, extremely absorbable nanoemulsions of oil in water. Such nanoemulsions are anticipated to show levels of bioavailability that far go beyond the absorption effectiveness these days’s macro or microemulsions of CBD Oil.

Low or commonly varying levels of CBD absorption and bioavailability might substantially impact the efficient delivery of the potential advantages of many CBD products on the market today.

Mr. Marco Alfonsi, CEO of Can B Corp, said: “It appears to us that PBI’s advancement UST platform is emerging as an essential market-changing innovation making it possible for a brand-new generation of CBD and other cannabinoid products to more effectively meet supplier objectives and customer needs. Offering reliable water solubility of cannabinoids, PBI’s UST-based BaroShear K45 system is expected to produce high CBD absorption rates and bioavailability from consumption or topical application of cannabinoid products.”

Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: “Notably, the optimized effectiveness for the customer also equates into allowing top-shelf makers like Can B Corp to accomplish targeted product results from much lower levels of cannabinoids in their marketed products. This should provide them a dramatic new expense efficiency, for both consumed or topically applied items. We likewise believe that Can B Corp’s routine use of our BaroShear K45 system will permit them to increase even more the existing high-quality level of their products.”

Mr. Peterson continued: “In addition to playing a substantial function in the predicted $89 billion(by 2024) cannabinoids market ( https://mordorintelligence.com/industry-reports/cannabis-market), we expect our trademarked UST technology platform to transform a large series of applications that extend across numerous multi-billion dollar markets, from dairy and other foods/beverages, to pharmaceuticals, nutraceuticals, and commercial applications. As the UST platform moves PBI into these large and amazing market chances, our company believe there will be steadily increasing shareholder and market price realization.”

About Can B Corp.

Can B Corp (OTC: CANBD) is a Health & Wellness business committed to providing the highest quality CBD products, nutritionals, consumer products, and associated medical devices. Can B Corp owns and operates a production facility under Pure Health Products in Lacey, Washington where all CBD based products are blended and packaged.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of ingenious, broadly enabling, pressure-based solutions for the around the world life sciences and other markets. Our items are based upon the unique homes of both constant (i.e., static) and alternating (i.e., pressure biking technology, or PCT) hydrostatic pressure. PCT is a patented making it possible for technology platform that uses rotating cycles of hydrostatic pressure in between ambient and ultra-high levels to securely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our main focus remains in the advancement of PCT-based items for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. In addition, significant new market opportunities have emerged in making use of our pressure-based technologies in the following locations: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma agreement services sector, and (2) using our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Innovation (” UST”) platform to (i) produce stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare greater quality, homogenized, extended shelf-life or space temperature level steady low-acid liquid foods that can not be successfully maintained utilizing existing non-thermal innovations.

Forward Looking Statements

This press release includes forward-looking statements. These threats, unpredictabilities, and other elements include, however are not limited to, the threats and unpredictabilities talked about under the heading “Risk Aspects” in the Company’s Annual Report on Type 10- K for the year ended December 31, 2018, and other reports submitted by the Company from time to time with the SEC.

To learn more about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:

Richard T. Schumacher, President and CEO
1-(508)-230-1828(T)

Kenneth F. Micciche, Director– UST Program
1-(508)-230-1829(F)

Marco Alfonsi, CEO, Can B Corp
1-(516)-565-9544(T)

SOURCE Pressure BioSciences, Inc.